Oxford Biodynamics PLC
LSE:OBD
Intrinsic Value
Oxford BioDynamics Plc is a biotechnology company, which engages in the discovery and development of novel epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. [ Read More ]
The intrinsic value of one
OBD
stock under the Base Case scenario is
0.9
GBX.
Compared to the current market price of 8.54 GBX,
Oxford Biodynamics PLC
is
Overvalued by 89%.
OBD's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
OBD or that its price is influenced by factors unrelated to fundamentals.
Oxford Biodynamics PLC's market capitalization is 26.6m GBX.
OBD stock price is 8.54 GBX.
OBD stock (0.9 GBX) is 89% less than its price (8.54 GBX).
OBD. Open DCF Valuation
OBD stock (0.9 GBX) is 89% less than its price (8.54 GBX). Open Relative Valuation
OBD.
OBD's Revenue has been growing by 4% per year for the last 3 years.
OBD's D/E (Debt to Equity) is very low and is equal to 0.93.
OBD has positive Net Debt. This means that the company has more debt (6m GBP) than cash and short-term investments (5m GBP).
OBD's Altman Z-Score is equal to 2.23.
OBD has positive Gross Profit for the last twelve months.
OBD's long-term assets (16m GBP) exceed its long-term liabilties (10m GBP).
OBD's short-term assets (7m GBP) exceed its short-term liabilties (4m GBP).
OBD's Revenue has grown by an exceptional 231% over the past 12 months.
OBD's ROE (Return on Equity) has significantly decreased in the last 3 years from -42% to -251%, and is approaching profitability.
OBD's ROIC (Return on Invested Capital) has significantly increased in the last 3 years from -209% to -106%, and is approaching profitability.
OBD has negative Operating Income for the last twelve months.
OBD has negative Net Income for the last twelve months.
OBD's ROE (Return on Equity) for the past 12 months is negative and is equal to -251%.
OBD's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -106%.
OBD has negative Free Cash Flow for the last twelve months.
OBD has negative three-year average ROE (Return on Equity): -102%. The company is not efficient at transforming stockholders' equity into net income.
OBD has negative three-year average ROIC (Return on Invested Capital): -133%. The company is not efficient at using invested capital to generate operating income.
OBD doesn't generate enough operating income (-10m GBP) to safely cover interest payments on its debt (213k GBP).
Valuation Backtest
Oxford Biodynamics PLC
Run backtest to discover the historical profit from buying and selling
OBD
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Oxford Biodynamics PLC
Balance Sheet Decomposition
Oxford Biodynamics PLC
| Current Assets | 7.2m |
| Cash & Short-Term Investments | 5.3m |
| Receivables | 1.6m |
| Other Current Assets | 274k |
| Non-Current Assets | 9m |
| PP&E | 7m |
| Intangibles | 1.9m |
| Other Non-Current Assets | 50k |
| Current Liabilities | 4m |
| Accounts Payable | 2.2m |
| Accrued Liabilities | 1.1m |
| Other Current Liabilities | 689k |
| Non-Current Liabilities | 6.1m |
| Long-Term Debt | 5.6m |
| Other Non-Current Liabilities | 450k |
Earnings Waterfall
Oxford Biodynamics PLC
|
Revenue
|
510k
GBP
|
|
Cost of Revenue
|
-244k
GBP
|
|
Gross Profit
|
266k
GBP
|
|
Operating Expenses
|
-10.4m
GBP
|
|
Operating Income
|
-10.2m
GBP
|
|
Other Expenses
|
-658k
GBP
|
|
Net Income
|
-10.8m
GBP
|
Free Cash Flow Analysis
Oxford Biodynamics PLC
OBD Profitability Score
Profitability Due Diligence
Oxford Biodynamics PLC's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Oxford Biodynamics PLC's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
OBD Solvency Score
Solvency Due Diligence
Oxford Biodynamics PLC's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Score
Oxford Biodynamics PLC's solvency score is 42/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
OBD Price Targets Summary
Oxford Biodynamics PLC
Shareholder Return
OBD Price
Oxford Biodynamics PLC
| Average Annual Return | -39.58% |
| Standard Deviation of Annual Returns | 17.61% |
| Max Drawdown | -95% |
| Market Capitalization | 26.6m GBX |
| Shares Outstanding | 311 856 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Oxford Biodynamics PLC
Country
Industry
Market Cap
Dividend Yield
Description
Oxford BioDynamics Plc is a biotechnology company, which engages in the discovery and development of novel epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. The firm is engaged in advancing personalized healthcare by developing and commercializing medicine tests for life-changing diseases. The company has developed a three dimensional (3D) genomic biomarker platform, EpiSwitch, which builds molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a range of indications. The platform discovers, evaluates, validates and monitors of biomarkers known as chromosome conformation signatures (CCSs). CCSs provides a compelling, stable framework from which changes in the regulation of a genome can be analyzed, long before the results of these epigenetic changes manifest themselves as obvious abnormalities. EpiSwitch supports precision medicine initiatives, including prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring.
Contact
IPO
Employees
Officers
The intrinsic value of one
OBD
stock under the Base Case scenario is
0.9
GBX.
Compared to the current market price of 8.54 GBX,
Oxford Biodynamics PLC
is
Overvalued by 89%.
You don't have any saved screeners yet
